While still largely a new phenomenon, biosimilars are here to stay—and this year will only bring more of them to market.
Pharmacy Best Practices
WalletHub released a study on Highest Drug Use by State to highlight the areas that stand to be most affected. Here are the top 10.
What experts say will be the year’s biggest problems, and what can be done about them.
As pharmaceuticals grow to consume more and more of the healthcare dollar, traditional care models need to change in order to deliver the best healthcare outcomes and real value. Here are five new models on the rise.
With all eyes on drug prices, payers are looking to biosimilar agents to cut costs—and improve patient outcomes.
In these arrangements, drug companies must partially reimburse insurers if the drug fails to earn its keep. Will COPD drugs be included in such arrangements?
Two recent studies on antibiotic use may indicate that antibiotic prescribing could be improving over time, but there’s room for improvement. Here’s four takeaways to get even better.
Despite a scolding from President Trump over drug price hikes, drug giant Pfizer announced it will raise the prices of 41 medications in January. That’s 10% of its entire drug portfolio.
This comprehensive, pay-for-performance approach drives clinical quality and affordability.
Biosimilars hold great cost savings promises for payers and patients alike—but only if prescribers and patients are willing to make the switch.